The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000560392
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
15/04/2026
Date registered
Help: Date registered
1/05/2026
Date last updated
Help: Date last updated
1/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
1/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Feasibility of a physiotherapy-led outpatient model of managing sleep apnoea in people with spinal cord injury
Scientific title
Feasibility of a physiotherapy-led outpatient model of managing sleep apnoea in people with spinal cord injury
Additional trial identifiers [1] 316815 0
MRFF2039772
Universal Trial Number (UTN)
Trial acronym
FASST-SCI
Related trial records

Health condition
Health condition(s) studied:
sleep apnoea 341162 0
spinal cord injuries 341459 0
Condition category
Condition code
Respiratory 337521 337521 0 0
Sleep apnoea
Neurological 337522 337522 0 0
Other neurological disorders
Physical Medicine / Rehabilitation 337523 337523 0 0
Physiotherapy
Injuries and Accidents 337738 337738 0 0
Other injuries and accidents

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The FASST-SCI care model: Patients of two statewide spinal cord injury (SCI) services (Victoria and Queensland) will be screened for risk of sleep apnoea by research or clinic staff prior to or at their routine outpatient appointment. Those at risk will be referred to a highly trained neuro-respiratory physiotherapist, located within the health service, for ambulatory investigations and management. “At-risk” is defined as people with SCI who:
- are not currently treated for sleep disordered breathing (SDB) (with positive airway pressure therapy or mandibular advancement device) AND
- have not been investigated for SDB with an overnight sleep study in the previous 3 years, unless this investigation identified SDB and the person is not on treatment.

Research or clinic staff will discuss the FASST-SCI clinic with those identified as "at risk". If agreeable, the spinal doctor will refer the patient to the FASST-SCI clinic where the physiotherapist will perform or arrange the following investigations:
- Symptoms and history
- Resting oxygen saturation (SpO2), daytime, upright, awake
- Handheld spirometry
- A Level 3 home sleep study (Resmed ApneaLinkAir), conducted in the patient’s home. The home sleep study is a portable device to be worn for 1 night. The device measures oxygen saturation with an oximeter worn on the finger, nasal flow with nasal prongs, and respiratory effort with a band around the abdomen.

The physiotherapist will meet with a respiratory physician to discuss the results and collectively determine risk of hypoventilation or other respiratory complications and whether referral to a respiratory physician for further investigations is needed. The following risk factors for sleep-related hypoventilation will be considered by the FASST-SCI physiotherapist and respiratory physician: Resting awake upright SpO2 < 93%; Presence of regular opiate medication; Presence of regular morning headaches; Body Mass Index > 35kg/m2; Forced Vital Capacity (FVC) <50% predicted and/or FVC<1.8L; SpO2 10% of total sleep time (T90%); Recurrent lower respiratory tract infections requiring antibiotic therapy in the community in the preceding 12 months; Documented left ventricle ejection fraction (LV EF) <35% on echocardiogram in the last 12 months.
The physiotherapist will collate this information during their initial FASST-SCI appointment, and the results will be discussed with the respiratory physician to determine the risk of harm and whether referral to a respiratory physician for further investigation of hypoventilation is needed. If the person is deemed to be a risk of hypoventilation, they will be referred to a respiratory physician and exit the FASST-SCI clinic.

For those who do not require further investigation for possible underlying hypoventilation, the physiotherapist (with respiratory physician support and endorsement) will establish if treatment-indicated sleep apnoea is present. Treatment indicated sleep apnoea is defined as:
- Apnoea Hypopnoea Index (AHI) and/or 3% Oxygen Desaturation Index (ODI) = 20/hr from overnight sleep study OR
- AHI and/ or 3%ODI =10 and <20/hr with symptoms (and considering patient preferences and suitability for treatment).

Those who do not meet these criteria for diagnosis will be discharged from the FASST-SCI clinic and referred to their GP or a respiratory physician where appropriate. Participants diagnosed with sleep apnoea and recommended treatment will be referred to a community-based continuous positive airway pressure (CPAP) provider for treatment initiation. The referral will include the recommended parameters in which to commence CPAP (i.e. pressure, mode etc), as determined by the FASST-SCI physiotherapist, in collaboration with the respiratory physician. Approximately 1-2 weeks prior to their initial appointment with the CPAP provider, the patient will be offered a psycho-education session delivered by the FASST-SCI physiotherapist, to prepare them for treatment and maximise uptake and adherence, Following CPAP initiation, the physiotherapist will contact the participant in the first week and work with the CPAP provider and participant over the subsequent 3 months to troubleshoot any issues, assess the risk of hypoventilation, and progress treatment as needed. Review appointments will be face-to-face or via telehealth (video-conferencing or telephone). Review appointments will include assessment of morning headaches, changes in symptoms, daytime SpO2 (if face-to-face), and treatment usage and side effects. Another home sleep study may be conducted if clinically indicated. Adjustments to masks and pressures will be made as required. Review appointments will be conducted as needed; there is no minimum or maximum number. After 3 months the person will be discharged from the FASST-SCI clinic and referred to their GP or a respiratory specialist for ongoing care, as needed.

Nested Mandibular Advancement Device (MAD) study (Victorian site only): Patients of the Victorian Spinal Cord Service, who are diagnosed with sleep apnoea and recommended treatment, will be offered the choice of treatment with CPAP or MAD. A maximum of 30 participants will be able to choose MAD, after which only CPAP will be available. Those who choose CPAP will be managed according to the protocol described above. Those who choose MAD will be referred to a specialist sleep dentist for a suitability assessment (including a full dental and oral examination). Prior to their dentist appointment, they will attend the online psycho-education session, delivered online by the FASST-SCI physiotherapist, as described earlier. The MAD will initially be set to 50% of maximum protrusion capacity. Level of protrusion is defined as the position between maximal retrusion and maximal protrusion. MADs will be fitted with a DentiTrac thermosensitive microsensor (Braebon Medical Corporation, Kanata, Canada) to assess objective adherence. The customised MAD will be delivered to the FASST-SCI physiotherapist for fitting, education, titration, and troubleshooting, with dentist support as required. Briefly, titration will involve advancing the mandible within the participants comfort levels, usually around 70-75% maximal protrusion. Titration will be guided by participant comfort. The number of times a participant is contacted will vary depending on time taken to achieve maximal protrusion. There is no set number of review appointments. However, adjustments will be made weekly depending upon participant comfort levels. Participants in this treatment pathway will undergo the same assessments for hypoventilation risk and treatment response as those using CPAP. They will receive the same treatment support, progression and ongoing care. After 3 months, they will be discharged from the FASST-SCI clinic to their GP, dentist, or respiratory physician, as clinically needed. The same referral pathways for those experiencing symptoms of hypoventilation and poor treatment response will apply.
Intervention code [1] 333733 0
Diagnosis / Prognosis
Intervention code [2] 333734 0
Early detection / Screening
Intervention code [3] 333735 0
Treatment: Devices
Description of the comparator or control
No control group.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345109 0
Feasibility.
Timepoint [1] 345109 0
Within 90 days of risk screening outpatient appointment.
Secondary outcome [1] 460487 0
Feasibility
Timepoint [1] 460487 0
Within 60 days of initial FASST-SCI assessment.
Secondary outcome [2] 460488 0
Feasibility
Timepoint [2] 460488 0
Within 60 days of referral for treatment.
Secondary outcome [3] 460493 0
Feasibility
Timepoint [3] 460493 0
90 days post treatment initiation.
Secondary outcome [4] 460501 0
Feasibility
Timepoint [4] 460501 0
3 months post baseline FASST-SCI assessment.
Secondary outcome [5] 460502 0
Treatment adherence
Timepoint [5] 460502 0
1 week, 3 months, 6 months and 12 months post treatment initiation.
Secondary outcome [6] 460503 0
Daytime state sleepiness
Timepoint [6] 460503 0
Baseline FASST-SCI assessment, 3 months, 6 months and 12 months post treatment initiation (or post baseline FASST-SCI assessment if treatment not initiated).
Secondary outcome [7] 460504 0
Daytime trait sleepiness
Timepoint [7] 460504 0
Baseline FASST-SCI assessment, 3 months, 6 months and 12 months post treatment initiation (or post baseline FASST-SCI assessment if treatment not initiated).
Secondary outcome [8] 460505 0
Sleep Quality
Timepoint [8] 460505 0
Baseline FASST-SCI assessment, 3 months, 6 months and 12 months post treatment initiation (or post baseline FASST-SCI assessment if treatment not initiated).
Secondary outcome [9] 460506 0
Preference-weighted Health-related Quality of Life
Timepoint [9] 460506 0
Baseline FASST-SCI assessment, 3 months, 6 months and 12 months post treatment initiation (or post baseline FASST-SCI assessment if treatment not initiated).
Secondary outcome [10] 460507 0
Depression
Timepoint [10] 460507 0
Baseline FASST-SCI assessment, 3 months, 6 months and 12 months post treatment initiation (or post baseline FASST-SCI assessment if treatment not initiated).
Secondary outcome [11] 460508 0
Anxiety
Timepoint [11] 460508 0
Baseline FASST-SCI assessment, 3 months, 6 months and 12 months post treatment initiation (or post baseline FASST-SCI assessment if treatment not initiated).
Secondary outcome [12] 460859 0
Pain indication
Timepoint [12] 460859 0
Baseline FASST-SCI assessment, 3 months, 6 months and 12 months post treatment initiation (or post baseline FASST-SCI assessment if treatment not initiated).
Secondary outcome [13] 460860 0
Pain interference (day to day activities)
Timepoint [13] 460860 0
Baseline FASST-SCI assessment, 3 months, 6 months and 12 months post treatment initiation (or post baseline FASST-SCI assessment if treatment not initiated).
Secondary outcome [14] 460861 0
Pain interference (sleep)
Timepoint [14] 460861 0
Baseline FASST-SCI assessment, 3 months, 6 months and 12 months post treatment initiation (or post baseline FASST-SCI assessment if treatment not initiated).
Secondary outcome [15] 460865 0
Pain intensity
Timepoint [15] 460865 0
Baseline FASST-SCI assessment, 3 months, 6 months and 12 months post treatment initiation (or post baseline FASST-SCI assessment if treatment not initiated).
Secondary outcome [16] 460866 0
Participation (paid work)
Timepoint [16] 460866 0
Baseline FASST-SCI assessment, 3 months, 6 months and 12 months post treatment initiation (or post baseline FASST-SCI assessment if treatment not initiated).
Secondary outcome [17] 460867 0
Participation (volunteer work)
Timepoint [17] 460867 0
Baseline FASST-SCI assessment, 3 months, 6 months and 12 months post treatment initiation (or post baseline FASST-SCI assessment if treatment not initiated).
Secondary outcome [18] 460868 0
Participation (education)
Timepoint [18] 460868 0
Baseline FASST-SCI assessment, 3 months, 6 months and 12 months post treatment initiation (or post baseline FASST-SCI assessment if treatment not initiated).
Secondary outcome [19] 460869 0
Participation (household activities)
Timepoint [19] 460869 0
Baseline FASST-SCI assessment, 3 months, 6 months and 12 months post treatment initiation (or post baseline FASST-SCI assessment if treatment not initiated).
Secondary outcome [20] 460870 0
Participation (spare time activities)
Timepoint [20] 460870 0
Baseline FASST-SCI assessment, 3 months, 6 months and 12 months post treatment initiation (or post baseline FASST-SCI assessment if treatment not initiated).
Secondary outcome [21] 460873 0
Treatment side effects (CPAP)
Timepoint [21] 460873 0
1 week post treatment initiation; 3 months post treatment initiation.
Secondary outcome [22] 460944 0
Treatment side effects (MAD)
Timepoint [22] 460944 0
1 week post treatment initiation; 3 months post treatment initiation.
Secondary outcome [23] 460945 0
Goal attainment
Timepoint [23] 460945 0
3 months post treatment initiation.

Eligibility
Key inclusion criteria
• Adults living with SCI in the community (tetraplegia and paraplegia; traumatic and non-traumatic causes)
• Attending the outpatient clinics of the Victorian and Queensland Spinal Cord Services.
• Not currently treated for sleep disordered breathing (i.e. positive airway pressure therapy or MAD)
• Has NOT been investigated for sleep disordered breathing with an overnight sleep study in the last 3 years OR diagnosed with sleep disordered breathing in the last 3 years and NOT currently on treatment.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
• Investigated for sleep disordered breathing in the previous 3 years, with a report indicating no sleep disordered breathing.
• Significant, inadequately managed, mental health issues / behaviours of concern.
• Unable to provide informed consent.

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis
Proportions of participants receiving components of the care model, frequencies of adverse events, time to receiving components of the care model, and descriptions of sample characteristics. The exact (Clopper-Pearson) two-sided 95% confidence interval for a single proportion will be used to obtain the confidence interval for the primary feasibility outcome and for other binary feasibility outcomes. The Kaplan-Meier estimator will be used to summarise time-to-event outcomes. Statistical analysis of patient clinical outcomes will be primarily descriptive: number and percentage for categorical variables, mean and standard deviation or median and interquartile range will be reported for continuous variables.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Recruitment hospital [1] 29400 0
Austin Health - Austin Hospital - Heidelberg
Recruitment hospital [2] 29401 0
Princess Alexandra Hospital - Woolloongabba
Recruitment postcode(s) [1] 45721 0
3084 - Heidelberg
Recruitment postcode(s) [2] 45722 0
4102 - Woolloongabba

Funding & Sponsors
Funding source category [1] 321409 0
Government body
Name [1] 321409 0
Australian Department of Health, Disability and Ageing, Medical Research Future Fund (MRFF)
Country [1] 321409 0
Australia
Funding source category [2] 321633 0
Charities/Societies/Foundations
Name [2] 321633 0
ResMed Foundation
Country [2] 321633 0
United States of America
Funding source category [3] 321634 0
Charities/Societies/Foundations
Name [3] 321634 0
Harold and Cora Brennen Foundation
Country [3] 321634 0
Australia
Funding source category [4] 321635 0
Charities/Societies/Foundations
Name [4] 321635 0
Institute for Breathing and Sleep
Country [4] 321635 0
Australia
Primary sponsor type
University
Name
University of Melbourne
Address
Country
Australia
Secondary sponsor category [1] 324153 0
None
Name [1] 324153 0
Address [1] 324153 0
Country [1] 324153 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319948 0
Austin Health Human Research Ethics Committee
Ethics committee address [1] 319948 0
Ethics committee country [1] 319948 0
Australia
Date submitted for ethics approval [1] 319948 0
01/12/2025
Approval date [1] 319948 0
16/03/2026
Ethics approval number [1] 319948 0
HREC/30260/Austin-2025

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148922 0
A/Prof Marnie Graco
Address 148922 0
Austin Hospital, 145 Studley Rd, Heidelberg, VIC 3084, Australia
Country 148922 0
Australia
Phone 148922 0
+61 3 94963811
Fax 148922 0
Email 148922 0
Contact person for public queries
Name 148923 0
Marnie Graco
Address 148923 0
Austin Hospital, 145 Studley Rd, Heidelberg, VIC 3084, Australia
Country 148923 0
Australia
Phone 148923 0
+61 3 94963811
Fax 148923 0
Email 148923 0
Contact person for scientific queries
Name 148924 0
Marnie Graco
Address 148924 0
Austin Hospital, 145 Studley Rd, Heidelberg, VIC 3084, Australia
Country 148924 0
Australia
Phone 148924 0
+61 3 94963811
Fax 148924 0
Email 148924 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• All de-identified individual participant data
What types of analyses could be done with individual participant data?
• Systematic reviews and meta-analyses
• Studies exploring new research questions
• Health economic analyses
• Studies testing whether findings can be repeated or confirmed
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
Not yet decided
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.